Back to News
Market Impact: 0.48
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Viking Therapeutics shares surged 36% on Sept. 22 after new maintenance data for VK2735 showed patients retained most weight loss when moving from weekly injections to every-other-week or monthly dosing. The results improve the commercial differentiation potential of Viking's GLP-1/GIP obesity candidate by supporting less frequent maintenance dosing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
VKTX0.88
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- These funds tout hefty income tied to the tech trade – if you’re willing to deal with the complexity
- Street Calls of The Week
- Meta’s $25 Billion Bond Sale Highlights Shifting Landscape for Tech Debt
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Coffee giant Dutch Bros made all of its executives, including the CEO, do a two-week bootcamp where they learned how to pour drinks and run stores